IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives
IMV Inc. , a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced... | May 1, 2023